<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37F4BB89-B409-45D2-999B-9CA119DEF5E3"><gtr:id>37F4BB89-B409-45D2-999B-9CA119DEF5E3</gtr:id><gtr:name>Department of Cardiothoracic Surgery</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Sch of Biomedical Sciences</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37F4BB89-B409-45D2-999B-9CA119DEF5E3"><gtr:id>37F4BB89-B409-45D2-999B-9CA119DEF5E3</gtr:id><gtr:name>Department of Cardiothoracic Surgery</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A3FB9677-92E9-4082-ABBF-045A34814805"><gtr:id>A3FB9677-92E9-4082-ABBF-045A34814805</gtr:id><gtr:firstName>Olga</gtr:firstName><gtr:otherNames>Lucia</gtr:otherNames><gtr:surname>Moncayo Nieto</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600457"><gtr:id>86508B27-8609-43CD-B4BD-649B63DEFC1F</gtr:id><gtr:title>Differential effects of methicillin-resistant and methicillin-sensitive Staphylococcus aureus on nasal and pulmonary inn</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0600457</gtr:grantReference><gtr:abstractText>?Superbugs? (bacteria capable of evading antibiotics) continue to increase steadily in hospitals and in the community. The superbug associated with the greatest public notoriety and clinical significance is methicillin-resistant Staphylococcus aureus (MRSA). MRSA can cause devastating pneumonia and septicaemia. These complications are inevitably preceded by a period of ?colonisation?, referring to a state where the MRSA lives in selected sites (eg the nose) without causing clinical illness. This stimulates the intriguing question of why the nose tolerates MRSA while the lung responds with exuberant inflammatory responses.
My application will test the hypothesis that the nose tolerates MRSA because (relative to the lung) it is deficient in molecules (called Toll-like receptors) that recognise bacteria on human cells, and because MRSA specifically switches off production of antibacterial molecules in the nose. These studies are likely to improve significantly understanding of how different parts of the body react to bacteria. In addition, the lining of the nose cannot ?eat? (and therefore clear) MRSA efficiently. The second part of my project will involve transferring ?eating? genes to nasal cells in the lab and observing clearance of MRSA. This novel gene therapy approach represents a potential future treatment for colonisation and infection caused by MRSA.</gtr:abstractText><gtr:technicalSummary>Colonisation of the nose with methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) results in a relatively ?silent? immunological response, whereas contact with distal airway epithelium results in an exuberant inflammatory response. The aims of this proposal are to develop a greater understanding of the mechanisms underlying this dichotomy and to develop novel strategies for eradication of MRSA. The specific objectives are to address two key hypotheses;
a) MRSA colonisation of nasal epithelium is established through induction of Toll-interacting protein (Tollip) and down-regulation of antimicrobial peptides (AMPs) with known activity against MRSA;
b) Genetic augmentation of the phagocytic receptor Fc RIIa in nasal epithelium will drive effective clearance of MRSA.
Primary human nasal epithelial cells, primary human pulmonary epithelial cells and established human nasal and pulmonary epithelial cell lines will be used to study the effects of MRSA/MSSA exposure on expression of Tollip, TLRs and AMPs. The mechanisms by which MRSA/MSSA affect signalling through TLRs will be investigated. Mechanisms by which expression of the AMP secretory leukocyte protease inhibitor is suppressed will be assessed by analysing the transcriptional factors involved in gene regulation. Gene transfer of Tollip will be used to determine whether tolerance to MRSA/MSSA can be induced in pulmonary epithelial cells.
In an extension of these studies a non-viral vector expressing the phagocytic receptor Fc RIIa will be developed and applied to (classically non-phagocytic) nasal epithelial cells in the expectation that opsonised MRSA/MSSA will be phagocytosed. Studies in mice will determine whether this approach can be applied successfully in vivo. 
The proposal would provide diverse training in cell culture, molecular biology, vectorology, gene therapy, quantification of inflammatory cytokines, assessment of phagocytosis, assessment of helial apoptosis, confocal microscopy and animal models of inflammation. From a scientific perspective the proposal is likely to dissect mechanisms by which nasal and pulmonary epithelium mount divergent innate responses to potential pathogens. From a medical perspective the proposal may suggest novel therapeutic avenues for the eradication of MRSA/MSSA which may prove to be applicable to other important pulmonary pathogens.</gtr:technicalSummary><gtr:fund><gtr:end>2010-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>190255</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Cardiothoracic Surgery</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Differential responses from lung and nasal primary epithelial cells in response to bacterial ligands</gtr:description><gtr:id>79984179-0882-4BBB-8E83-461B28CADE7E</gtr:id><gtr:impact>The nasal epithelium seems to display a more pro-inflammatory phenotype when compared to their lung primary counterparts. This behaviour is very different when cell lines are used. Nasal carriage of Staphylococcus aureus is also associated with a pro-inflammatory cytokine production pattern. Collaborating with the surgical team has allowed comparison of nasal and lung epithelial cells from the same patient
Abstract submitted to the British Thoracic Society (BTS) 2010 winter meeting and accepted for an oral presentation</gtr:impact><gtr:outcomeId>938B53EAD0D-1</gtr:outcomeId><gtr:partnerContribution>Allowing access to patients undergoing lung resection or partial lobectomies in order to get tissue for the isolation of primary fibroblasts and Type II alveolar epithelial cells, as well as primary nasal epithelial cells</gtr:partnerContribution><gtr:piContribution>I have isolated primary nasal and Type II alveolar epithelial cells from healthy volunteers and patients with Lung Cancer undergoing thoracotomy. These have been stimulated with bacterial ligands in order to assess the different responses from the two compartments.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Panceltic Medical Microbiology meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EA08C679-CF5B-418A-93C3-9FC11CE09114</gtr:id><gtr:impact>Presentation of two posters at the Panceltic medical microbiology meeting. Attended by approx 100 health profesionals: microbiology consultants and junior doctors training in medical microbiology and virology, biomedical scientists

Increased awareness of my particular area of research within medical microbiology colleages</gtr:impact><gtr:outcomeId>k7p5ysLRxKk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A database of RNA, DNA, supernatants and whole cell lysates from primary nasal epithelial cells from healthy donors and lung cancer patients; as well as of primary type II alveolar epithelial cells from lung cancer patients, has been developed during this study in order to assess the fundamental questions of how do bacteria establish tolerance in the nasal epithelium and how is this response different from the lung epithelium.</gtr:description><gtr:id>88973A3F-0712-48B0-A4BC-8C0610998210</gtr:id><gtr:impact>The database of primary nasal and lung epithelial cells will be available to like minded researchers pending ethical permissions as appropriate.</gtr:impact><gtr:outcomeId>1559872970E</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Development of database of healthy volunteers and patients colonised by Staphylococcus aureus</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I implemented and optimised a protocol for isolating and culturing primary human lung epithelial cells: fibroblasts and type II alveolar epithelial cells from lungs from patients undergoing partial lobectomy or pneumonectomy due to lung cancer</gtr:description><gtr:id>F1C82293-5D3C-4810-A518-B9C904E8444B</gtr:id><gtr:impact>I provided the protocol to another group at the Centre for Inflammation Research (QMRI) in Edinburgh. I understand from informal conversations with the person involved in the protocol that the protocol has been working well. I have no further information regarding number of lungs processed.</gtr:impact><gtr:outcomeId>qfmoRyTttmR</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Development and implementation of protocol on isolation of human primary type II alveolar epithelial cell and primary human lung fibroblasts</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0861693C-D975-4B42-9BA9-DDFF96A16FC9</gtr:id><gtr:title>S81 Primary type II alveolar epithelial cells respond differentially to bacterial virulence factors</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f9d86a45d8a26e37bb7a8aed3be52c4"><gtr:id>3f9d86a45d8a26e37bb7a8aed3be52c4</gtr:id><gtr:otherNames>Nieto O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>Da16YnjUKbo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48DC505B-03A5-4DF9-9F60-82284D8822B5</gtr:id><gtr:title>Improving the use of sputum cultures in lower respiratory tract infection.</gtr:title><gtr:parentPublicationTitle>The journal of the Royal College of Physicians of Edinburgh</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee408bba342dd4a947cf503567e1cbe5"><gtr:id>ee408bba342dd4a947cf503567e1cbe5</gtr:id><gtr:otherNames>Moncayo-Nieto OL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1478-2715</gtr:issn><gtr:outcomeId>pm_15453_23_23734350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5296E38-FB80-4E00-84F0-1BD2DC8007CE</gtr:id><gtr:title>Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumonia.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7f730c06e18455fc8fcea0cdb66c2d"><gtr:id>6d7f730c06e18455fc8fcea0cdb66c2d</gtr:id><gtr:otherNames>Conway Morris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>015A029F6D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>612ED796-3FCA-4A21-BC2F-81924DC3BA39</gtr:id><gtr:title>Differential response to bacteria, and TOLLIP expression, in the human respiratory tract.</gtr:title><gtr:parentPublicationTitle>BMJ open respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee408bba342dd4a947cf503567e1cbe5"><gtr:id>ee408bba342dd4a947cf503567e1cbe5</gtr:id><gtr:otherNames>Moncayo-Nieto OL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2052-4439</gtr:issn><gtr:outcomeId>545a693f593f55.63710228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>655682DC-6BD7-4636-869C-557C2295C0E7</gtr:id><gtr:title>Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling.</gtr:title><gtr:parentPublicationTitle>Journal of medical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fa3380a9c902904e5b292cde31ae08e"><gtr:id>5fa3380a9c902904e5b292cde31ae08e</gtr:id><gtr:otherNames>Erridge C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2615</gtr:issn><gtr:outcomeId>875C96DCBB4</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600457</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>